Inhibitors | Comment | Organism | Structure |
---|---|---|---|
1,3,5-tris-4'-2''-[3'''-C-(beta-D-glucopyranosyl)-1''',2''',4'''-oxadiazol-5'''-yl]ethyl-1',2',3'-triazol-1'-ylmethylbenzene | trivalent inhibitor. The valency of the molecules influences slightly the inhibition of the enzyme whereas the presence of a spacer arm between the core and the pharmacophore moieties does not | Oryctolagus cuniculus | |
1,3,5-tris[3'-C-(beta-D-glucopyranosyl)-1',2',4'-oxadiazol-5'-yl]-benzene | trivalent inhibitor. The valency of the molecules influences slightly the inhibition of the enzyme whereas the presence of a spacer arm between the core and the pharmacophore moieties does not | Oryctolagus cuniculus |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Oryctolagus cuniculus | - |
- |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
muscle | - |
Oryctolagus cuniculus | - |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
glycogen + alpha-D-glucose 1-phosphate | - |
Oryctolagus cuniculus | glycogen + phosphate | - |
? |
Ki Value [mM] | Ki Value maximum [mM] | Inhibitor | Comment | Organism | Structure |
---|---|---|---|---|---|
0.48 | - |
1,3,5-tris-4'-2''-[3'''-C-(beta-D-glucopyranosyl)-1''',2''',4'''-oxadiazol-5'''-yl]ethyl-1',2',3'-triazol-1'-ylmethylbenzene | - |
Oryctolagus cuniculus | |
0.535 | - |
1,3,5-tris[3'-C-(beta-D-glucopyranosyl)-1',2',4'-oxadiazol-5'-yl]-benzene | - |
Oryctolagus cuniculus |